| Drug Name: |
Anti-inhibitor coagulant complex |
| Applications: |
For use in the control of bleeding episodes, perioperative management, and routine prophylaxis against bleeding episodes in hemophilia A and B patients with inhibitors. It is not indicated in the absence of factor VIII or IX inhibitors. |
| Examples of Clinical Use: |
Hemophilia A and B |
| Pharmacodynamics: |
FEIBA contains several clotting factors which act at various points in the caogulation cascade to promote thrombosis. |
| Mechanism of action: |
Factor VIIa present in FEIBA forms a complex with tissue factor and calcium which converts endogenous and FEIBA contained factor X to Xa. Endogenous and FEIBA contained factor Xa act as parrt of the prothrombinase complex to convert endogenous and FEIBA contained prothrombin to thrombin. Endogenous and FEIBA contained thrombin then cleave fibrinogen to insulouble fibrin and activate factor XIII which covalently cross-links fibrin to form a polymer mesh. FEIBA also contains factor IX and IXa which act as part of the tenase complex to convert factor X to Xa. Thrombin activates factor V, VII, and VIII as part of the amplification phase of the clotting cascade. These events promote the formation of blood clots to prevent or stop bleeding. |
| Affected organisms: |
Humans and other mammals |
| Targets: |
Target 1. Coagulation factor X; Target 2. Prothrombin; Target 3. Fibrinogen alpha chain; Target 4. Fibrinogen beta chain; Target 5. Coagulation factor XIII A chain; Target 6. Coagulation factor V; Target 7. Coagulation factor VIII; Target 8. Coagulation factor VII; Enzyme 1. Prothrombin; Enzyme 2. Coagulation factor VII; Enzyme 3. Coagulation factor VIII; Enzyme 4. Coagulation factor IX; Enzyme 5. Coagulation factor V |
